Results 1 to 10 of about 3,595 (167)

Study of the release kinetics of dalbavancin from bone allografts. [PDF]

J Mater Sci Mater Med
Bone infections are common and difficult to treat, and secondary bone defects, which are often observed, may require a bone allograft. In this case, the surgeon will add antibiotics (usually vancomycin) in direct contact with the bone graft during the ...
Erivan R, Bourzat N, Yessaad M, Villatte G, Descamps S, Boisgard S, Chennell P.   +6 more
europepmc   +3 more sources

Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus. [PDF]

Sci Rep
To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term ...
Morath B, Klein S, Chiriac U, Müller Y, Koeppel L, Frey O, Lanzinger H, Schlegel P, Hamed S, Nurjadi D, Ehlermann P, Karck M, Meyer AL.   +12 more
europepmc   +3 more sources

Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections. [PDF]

Antibiotics (Basel)
Introduction: Suppressive antibiotic therapy (SAT) is a therapeutic alternative for complex infections where a cure is considered unlikely or impossible. SAT involves the prolonged, often indefinite, administration of antibiotics, typically given orally,
Escudero-Sanchez R, Morata L, Buzón L, de la Villa S, Rico A, Nuñez Orantos MJ, Guio Carrion L, Tasias Pitarch M, Del Pozo JL, Barbero JM, Gómez-Junyent J, García Pais MJ, Bachiller Luque P, Martínez Marcos FJ, Cobo J, Geio Spanish Group For Osteoarticular Infections.   +15 more
europepmc   +3 more sources

Dalbavancin. [PDF]

CMAJ
Stevenson IR, Bai AD, Shchepanik K.
europepmc   +14 more sources

Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring. [PDF]

J Antimicrob Chemother
Dalbavancin is a long-acting lipoglycopeptide antibiotic with potent activity against Gram-positive bacteria. Approved for acute bacterial skin and skin structure infections, it is increasingly used off-label in prolonged or chronic infections, such as ...
Barco A, Cattaneo D, Cusato J.
europepmc   +2 more sources

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. [PDF]

JAMA
Importance Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access.
Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG, Holland TL, Antibacterial Resistance Leadership Group.   +48 more
europepmc   +2 more sources

Dalbavancin to facilitate early discharge in the treatment of complex musculoskeletal infections: a multi-centre real-life application [PDF]

Journal of Bone and Joint Infection
Dalbavancin is a lipoglycopeptide with a half-life of 14 d, significantly reducing the need for daily antibiotic dosing. Although dalbavancin is approved for acute bacterial skin and skin structure infections, its off-label use in complex musculoskeletal
T. Azamgarhi, S. Warren, A. Scobie, N. Karunaharan, C. Perez-Sanchez, R. Houghton, S. Hassan, J. Lourtet-Hascoët, J. Lourtet-Hascoët, H. Kershaw, P. Sendi, K. Saeed, K. Saeed   +12 more
doaj   +2 more sources

Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing. [PDF]

Antimicrob Agents Chemother
Dalbavancin is a long-acting lipoglycopeptide increasingly used off-label for complex Gram-positive infections requiring prolonged therapy. Its extended half-life enables simplified regimens, but interindividual pharmacokinetic variability and pathogen ...
Sayadi H, Gregoire M, Fromage Y, Ksentini M, Labriffe M, Monchaud C, Codde C, Faucher J-F, Boutoille D, Marquet P, Woillard J-B.   +10 more
europepmc   +2 more sources

Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series. [PDF]

Antimicrob Agents Chemother
Retained hardware/prosthetic infections frequently require antimicrobial suppression therapy. Treatment options are often limited by resistance, allergies, and dosing frequencies.
Kufel WD, Tudahl K, Hutson P, Mahapatra R, Rose W, Volk C.   +5 more
europepmc   +2 more sources

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis

Case Reports in Dermatology
Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases
Jina Bai, Emily Frech Preciado, Mary Baxter Harlow, Nina Blank   +3 more
doaj   +2 more sources